regulate the sinusoidal flow 6 and to modulate various metabolic functions in hepatocytes. 7, 8 The majority of the biological functions of NO appears to be mediated primarily by the activation of soluble guanylate cyclase (sGC) concomitant with a cyclic guanosine monophosphate (cGMP) increase.
The majority of the biological functions of NO appears to be mediated primarily by the activation of soluble guanylate cyclase (sGC) concomitant with a cyclic guanosine monophosphate (cGMP) increase. 9 Through this pathway, endothelium-derived NO induces the relaxation of vascular smooth muscle and inhibits platelet aggregation. 10 Unfortunately, NO is also cytotoxic in some circumstances. In ischemia/reperfusion, macrophages, neutrophils, and endothelial cells may be activated to produce both superoxide and NO, which leads to form peroxynitrite and hydroxy radicals, 11 causing tissue injury. 5, 8 These reactions are the direct effects of NO, being independent of cGMP. 11, 12 The purpose of this study was to examine the effect of cGMP on warm ischemia/reperfusion injury in the porcine liver, using a membrane-permeable cGMP analog, 8-bromoguanosine 3Ј, 5Ј monophosphate (8-Br-cGMP). We therefore assumed that the supplementation of cGMP instead of NO or NO donors might abate vascular dysfunction by modulating the vasodilatation of microcirculation without producing toxic radicals by ischemia/reperfusion in the porcine liver.
Materials and Methods

Surgical Preparation
A total of 12 white pigs, weighing 18.6-28.9 kg, were fasted for 24 h with water available, and anesthetized with intramuscular pentobarbital sodium (10 mg/kg) and ketamine hydrochloride (20 mg/kg). An ear vein was then cannulated, and anesthesia was maintained with continuous infusion of pentobarbital sodium (1.0 mg/kg per h) and ketamine hydrochloride (1.0 mg/ kg per h). Respiration was mechanically controlled
Introduction
Nitric oxide (NO) is well known to be an endothelial relaxing factor, 1, 2 and is reported to regulate the microcirculation 3 and to be related with the pathogenesis of various liver diseases. 4 NO is produced by all major cells, including hepatocytes, Kupffer cells, endothelial cells, and stellate cells. 5 In the liver, NO was shown to using a respirator after tracheotomy. The right carotid artery was cannulated for the measurement of mean arterial blood pressure (MAP) and the withdrawal of blood samples. Via the right subclavian vein, a thermodilution cardiac output (CO) catheter was inserted for the measurement of CO and infusion of lactate Ringer solution supplemented with sorbitol (10 ml/kg per h). After laparotomy, the common bile duct was cannulated for the measurement of bile outflow. After splenectomy, a bypass tube (Anthron bypass tube VTT-4860, Toray, Tokyo, Japan) was placed between the splenic vein and left jugular vein for portal drainage. For the measurement of the portal venous pressure (Ppv), a catheter was inserted into the portal vein via the side branch to within 1 cm of the hilum of the liver. Blood-flow probes were placed around the common hepatic artery and the portal vein. Two laser Doppler flow probes were also placed on the surface of the right and left hepatic lobes. After the completion of surgical preparations, the abdominal wall was closed to minimize the loss of body temperature and body fluid.
Next, severe hepatic ischemia was induced by crossclamping the hepatoduodenal ligament for 60 min. 8-BrcGMP (Sigma, St. Louis, MO, USA) sodium salt (1.0 mg/kg per h) was administered into the portal vein 30 min before and after ischemia for each group of six pigs (cGMP group), while saline water was administered in the same way to the other six (control group).
Evaluation of Hemodynamics
PVF and HAF were measured with ultrasound transit time flow probes (T201 Transonic Systems, Advance, Tokyo, Japan) and the hepatic tissue blood flow (HTBF) was estimated by a laser Doppler flowmeter (ALF21D, Advance). The blood pressure was measured with pressure transducers (San-ei Polygraph 360 system, NEC, Tokyo, Japan). These signals were all recorded by a pen recorder. PVF, HAF, and HTBF are presented as a percentage of each value before ischemia.
The blood pressure and blood flow were measured at preischmia, during ischemia, at 5 min after the start of reperfusion, and every 30 min up to 180 min after the start of reperfusion. The CO was measured at preischemia and at every 60 min up to 180 min after the start of reperfusion.
Measurement of Liver Enzymes
As the indicator of ischemic hepatic damage, asparate aminotransferase (AST) and lactate dehydrogenase (LDH) were assessed 60, 120, and 180 min after commencement of reperfusion, and compared with each value before ischemia.
Measurement of the Discharge
As an indicator of global liver function, the bile discharge was examined, collected before ischemia, and at 60, 120, and 180 min after the start of reperfusion, expressed as a percentage of each value before ischemia. Bile was collected from the cannula at 30-min intervals at each corresponding point.
Measurement of cGMP Level in Hepatic Tissue
Wedge liver biopsies collected before ischemia and at 60, 120, and 180 min after the start of reperfusion were used to measure the cGMP level in the hepatic tissue using a cGMP assay kit (Yamasa Soy Sauce, Tokyo, Japan).
Data Analysis
A statistical analysis was done using Fisher's t-test and repeated-measures ANOVA to compare the variables between the two groups. The pressure data, serum levels of liver enzymes, and cGMP levels of hepatic tissue are expressed as mean Ϯ SD, and other data are expressed as mean Ϯ SEM. When a P value was less than 0.05, the difference was considered to be statistically significant.
All animals received humane care in accordance with the Principles of Laboratory Animal Care formulated by the National Society of Medical Research, and the Guide of the National Academy of Sciences, published by the U.S. National Institutes of Health (NIH Publication no. 80-23, revised in 1978).
Results
MAP, Ppv, and CO
The MAP of both groups did not change significantly throughout the experiment. The CO decreased during the ischemia in both groups but recovered after reperfusion in both groups, showing no significant difference between the groups. On the other hand, Ppv of the cGMP group was generally lower than that of the control group and the difference was significant at 5 min after reperfusion (Table 1) .
PVF and HAF
PVF decreased to 72.5% Ϯ 9.4% and 56.9% Ϯ 5.5% of each control value after 120 min of reperfusion in the cGMP group and control group, respectively. Consequently, there was a significant difference between the two groups after 120 min of reperfusion (P Ͻ 0.05 for each time point). The PVF in the cGMP group was significantly higher than that of the control group (P ϭ 0.044). The PVF in the control group gradually decreased after reperfusion, whereas that in the cGMP group was preserved at the same level after reperfusion (Fig. 1) . HAF increased after reperfusion in both groups, reaching 153.3% Ϯ 18.7% and 130.3% Ϯ 14.9% at the 180-min time point in the cGMP group and control group, respectively (Fig. 2) . HAF in the cGMP group tended to be higher than that of the control group at each time point, but the difference was not significant.
HTBF
HTBF was 99.5% Ϯ 7.3% and 71.6% Ϯ 9.0% of each control value after 120 min of reperfusion in the cGMP and control groups, respectively. There was a significant difference between the two groups after 120 min of reperfusion (P Ͻ 0.05 for each time point) (Fig. 3) . HTBF after reperfusion in the cGMP group was higher than that of the control group, and the difference was significant (P ϭ 0.017). HTBF of the cGMP group was preserved at the same level after reperfusion.
Liver Enzyme Levels and Bile Discharge
There was no significant difference between the two groups regarding the serum level of liver enzymes ( Table 2 ). The percentage change of the bile discharge was 96.5% Ϯ 17.1% and 51.1% Ϯ 26.4% at 120 min, and (Fig. 4) . The bile discharge after reperfusion in the cGMP group demonstrated a significant difference after 120 min of reperfusion.
cGMP Level of the Hepatic Tissue
Before ischemia, there was no significant difference in the cGMP level of hepatic tissue between the two groups (Fig. 5) . The level in the cGMP group increased remarkably after reperfusion as compared with the preischemic level, and the difference was significant: 0.057 Ϯ 0.002 vs 1.471 Ϯ 0.566, 0.690 Ϯ 0.469, and 0.490 Ϯ 0.225 pg/mg protein at 60 min, 120 min, and 180 min after reperfusion (P Ͻ 0.01 for each), respectively. The level in the control group also increased from 0.047 Ϯ 0.005 pg/mg before ischemia to 0.090 Ϯ 0.031 pg/mg protein at 60 min after reperfusion, but the difference was not significant. As a result, the cGMP level of hepatic tissue was significantly higher in the cGMP group than in the control group at all points of reperfusion (P Ͻ 0.01 for each).
Discussion
NO is considered to play a protective role for tissue in the pathogenesis of various liver diseases, 13, 14 and in ischemia/reperfusion it plays a very important role in maintaining vascular homeostasis, 4, 6, 15 because NO has functions such as mediating vasodilatation, 16 thus preventing neutrophil adherence to the endothelium, 17 maintaining endothelial barrier properties, 18 and inhibiting platelet aggregation. 10 However, NO by itself is also known to present cytotoxicity in some circumstances. Under oxidative stress such as inflammation and ischemia/reperfusion, NO and superoxide are generated by macrophages, neutrophils, and endothelial cells, and NO may combine rapidly with superoxide to form highly toxic peroxynitrite and hydroxy radical. 11, 12 Peroxynitrite has been shown to be the source of a strong oxidizing agent with properties identical to those of the hydroxy radicals, which may directly cause severe cell injury. This potentially deleterious interaction has been reported in the reperfusion injury of many organs, such as the heart 19 and lung. 20 On the other hand, NO is known to be an intercellular mediator. In cells, NO activates soluble guanylate cyclase (sGC), which results in an increase in the cGMP level. 9 cGMP then develops smooth muscle relaxation (vasodilatation) 16 and inhibits platelet aggregation. 10 This pathway is not concerned with producing superoxide and peroxynitrite. Therefore, attention has recently been focused on cGMP in the transplantation of lung 20 and in myocardial reperfusion injury. 21 Recent findings suggest that cGMP may play a protective role in hepatocytes, mediating the damage induced by hypoxia and reactive oxygen species, as a messenger of atrial natriuretic peptide (ANP). 22 It has been suggested that the beneficial actions of cGMP are not limited to vasodilatation but also extend to the attenuation of neutrophil infiltration.
17,18 Therefore, we hypothesized that the supplementation of cGMP instead of NO or NO donors might confer the beneficial vascular effects of NO, avoiding their potential toxicity by ischemia/reperfusion in the liver.
We used 8-Br-cGMP, which is a membranepermeable cGMP analog, in this study. This analog has a high potency as an activator and a high affinity for the cGMP-binding sites. 23 The dosage of 8-Br-cGMP used in the experiment was based on previous reports. 24, 25 The portal infusion of cGMP was selected to restrict this effect as much as possible in hepatic circulation, since cGMP has been reported to depress myocardial contractility. 25, 26 The continuous infusion was expected to supply a sufficient dose of cGMP to the hepatic tissue. Our results showed no significant difference in hemodynamics, including the cardiac output, between the cGMP and control groups, and the liver tissue level of cGMP was significantly higher in the cGMP group at all time points after reperfusion. We therefore consider that the dose (1.0 mg/kg) and administration route of cGMP (continuous infusion) may be efficient for evaluating the effects of cGMP using a 60-min total hepatic ischemia model. However, it remains to be clarified as to how cGMP, which passed through the liver and migrated into the systemic circulation, influenced any other organs.
Huguet et al. 27 reported that the interruption of hepatic blood flow in normothermia is safe for at least 60 min in human beings; it was also reported that 120 min of continuous ischemia was submitted without biochemical and/or pathologic damage in experimental surgery in pigs. 28 However, regarding the systemic hemodynamics in our preliminary experiment, PVF and HAF were unsettled after 120 min total hepatic ischemia, most likely due to problems with the portovenous bypass tube. To eliminate such inappropriate influences on the results, we selected an ischemic time of 60 min in this study.
We observed that both PVF and HTBF were significantly higher in the cGMP group than in the control group. cGMP was thus thought to reduce the portal vascular resistance against the enhanced production of endothelin, 3, 6 namely, the contractility of stellate cells was controlled 29 and platelet aggregation was inhibited. 10 Moreover, the discharge of bile, which was an indicator of liver function, was observed to increase after the start of reperfusion in the cGMP group. The improvement of HTBF might contribute to the increase of the bile discharge. A similar study also reported the supplementation of cGMP to increase the bile flow and biliary concentration. 30 NO suppression of the release of liver enzymes by cGMP was observed in this study. This was most likely due to the effect that the ischemic time of 60 min and the observation period of the reperfusion of 180 min might be too short to evaluate the effect of cGMP on the liver enzyme levels. This question should be elsewhere using other ischemic models.
In conclusion, an intraportal supplementation of 8-Br-cGMP ameliorated PVF and HTBF after warm ischemia/reperfusion of the porcine liver, with hemodynamic stability. The bile discharge, as an indicator of liver function, was increased by the cGMP supplementation. We propose that cGMP is beneficial for preserving hepatic circulation after surgery involving liver ischemia, such as that performed during an extended hepatectomy and/or liver transplantation.
